The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
Questions this briefing will address:
· What are the key challenges the CMOs are likely to face in the near- and long-term future? How can CMOs strategize to overcome these hurdles?
· What growth opportunities exist in the pharmaceutical contract manufacturing industry?
· In what ways is the pharmaceutical contract manufacturing industry likely to change to meet industry trends and dynamics?
· Who are the game-changing companies, and what are the disruptive technologies and business models?
· How should CMOs strategically position their assets with pharma companies?
Vitamin E is a powerful antioxidant that supports your health; however, intake still remains low among consumers globally. There is an ongoing discussion about the optimal vitamin E status and its role in addressing liver and brain health beyond nutritional recommendations.
New and ongoing research suggests that vitamin E at higher doses may help individuals at risk, such as those with age-related macular degeneration, cognitive impairment, and non-alcoholic fatty liver. It is important to revisit the required intake levels for vitamin E for these conditions and further research is needed to support qualified health claims.
Join us for the first in our webinar digest series to hear Prof. Jeffrey Blumberg, DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly discuss the emerging health benefits of vitamin E.
This information is solely for scientific informational purposes only and not intended for marketing and/or sales claims purposes.
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.
How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
Cell culture media is required for successful and reproducible research but the catalog is full of acronyms and various formulation tables. Classical mammalian cell culture media formulations are very diverse both in terms of the number available and the concentration of constituents. Additionally, each medium was designed for specific cell types and culturing conditions.
This webinar will cover:
•The composition, characteristics, environmental factors, and additional supplements required to create optimal conditions for growth and productivity.
•Determining the right formulation for your application.
•Serum usage and helpful tips for optimizing your culture conditions.
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has led numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
As part of a wider digitization initiative, Meander Medical Centre wanted to involve nurses in the development of an app that would help them deliver better patient care. The IT team and nursing staff worked with Dell Digital Business Services to design an app that would be used on the Dell Venue 11 Pro tablet, integrating with the hospital’s electronic medical record system.
Learn more as Dr. Scott Rader, Stratasys, and Dr. Vicknes Waran, Centre for Biomedical and Technology Integration (CBMTI) in Malaysia, discuss how 3D printing can reduce cost, improve care or increase speed at every step in the medical device value chain. This results in increased profitability, technology adoption and market responsiveness. Stratasys solutions shape clinical outcomes and corporate profit.
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.
UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?
Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
Join us to hear award-winning author Professor Wilfred Ngwa talk through his latest book Emerging Models for Global Health in Radiation Oncology. Highlighting the emerging models for global radiation oncology, this webinar is essential viewing for researchers, students, health professionals and anyone interested in the global oncology community.
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.
Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?
In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:
The impact of Brexit on UK Healthcare
The ramification of Brexit for pharma in the UK
What does the Brexit scenario mean for global pharma?
Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.
On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.
It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
The global pharmaceutical industry is witnessing an unprecedented era. Several new demand spaces such as innovative therapeutics (immuno-oncology), clinical diagnostics (liquid biopsy), and research tools (next-generation sequencing) have emerged, driving companies to sharpen their long-term positions. Fundamental behavioral shifts in these spaces are redefining the market. Companies are adopting a “beyond-the-pill” approach and increasing investments in innovations related to drug discovery, clinical trials, supply-chain solutions, and patient engagement. This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the life sciences industry.
This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
DocuSign helps sales organizations close deals faster — anywhere in the world. DocuSign offers greater visibility into a deal’s status, the ability to collect information so you don’t need to rekey data, and the ability to send out reminders so you can spend more time selling and less time tracking down signatures.
In this on-demand webinar, DocuSign customers will share their best practices for shortening the sales cycle and increasing the productivity of their teams by integrating DocuSign into the sales workflow.
Brian Driver, Salesforce
Elizabeth Guerra, LinkedIn
Watch this on-demand webinar from Ardent Partners, DocuSign, and Safeway for a compelling webinar presentation and discussion. The focus is on the strategies and tools that modern CPOs and their procurement teams can adopt in the pursuit to become more agile, collaborative, and innovative throughout their supplier contract lifecycle.
As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.
Medical education has the potential to affect a significant number of healthcare professionals’ (HCPs) clinical practice and so improve patients’ outcomes.
Nonetheless, achieving these goals requires medical education to move beyond didactic message delivery - that only improves HCPs’ awareness - to using many multi-channel educational interventions to drive real behaviour change.
In this webinar, Lucid will discuss why, as an industry, we should all be moving beyond our internal goals to think about how we can improve patient outcomes with all our programmes and share a process for creating measurable improvements.
The Ray Optics Module simulates electromagnetic wave propagation when reflection and refraction are the most important effects. This is the case when the wavelength is short compared with device size. Industrial applications include common optical components such as reflectors, monochromators, lenses and polarizers.
This webinar will introduce the tools in COMSOL Multiphysics® for analysis of geometrical optics, including ray intensity and polarization calculations; ray propagation in graded media; and multiphysics coupling to other physics such as heat transfer.
The webinar will include a live demo and conclude with a Q&A session.
In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.
This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.
With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.
As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.
This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
Skin cancer is by far the most prevalent cancer. Each year, approximately 3.4 million people in the US alone are diagnosed with some form of skin cancer. Skin cancer can be highly treatable if it is detected and classified early, and this detection and classification is often aided by immunohistochemistry. This presentation covers many of the basic science, facts, and statistics of skin cancer, as well as the utility of immunohistochemical testing with markers such as S-100, SOX-10, Ber-Ep4, and HHV-8 in the accurate diagnosis and survival rates of skin cancer. Continuing education credits for attending this webinar will be offered through the National Society of Histotechnology
Predictive assays are a key element of personalized healthcare because these assays aid physicians in selecting individuals who are most likely or least likely to benefit from specific therapies. In addition to analytical validation, predictive assays require clinical validation to establish their clinical utility. Krista Acosta, Manager, CDx Pharma Services Assay Development, Nicole Schechter, PSM, PMP, CDx Director, Project Leader and Alton Yates PhD, Senior Manager, Clinical Sciences Management, will address the development and performance differences between predictive assays developed under in vitro diagnostic regulations and laboratory developed tests.
The need to securely share your files quickly and easily while knowing what's going on with your business is extremely important. DocuSign's integration with Box allows you to select documents from Box you want to sign or send for signature and prepare it in just a few clicks. Completed documents automatically save back to Box and can be accessed from anywhere, on any device.
Join this webinar to learn:
- How to securely share files quickly
- How to be more productive regardless of what device or application you're using.
- How Salesforce automatically creates a workflow process with Box and DocuSign
See how the DocuSign and Box integration can help you improve contract processes, keep all documents digital and help you get business done in 2016.
Fully integrated with Salesforce, DocuSign helps users close more deals, faster. Your customers can sign contracts within minutes from anywhere, anytime and on any device. Sending a contract for electronic signature from Salesforce is simple: just click “Send with DocuSign” from any object. You can even generate and send contracts synced with data from Salesforce. When you automate time-consuming manual workflows, you eliminate rekeying of data and increase your productivity.
Join DocuSign and Outbrain, the global leader in content marketing, for a compelling webinar presentation and discussion.
This webinar will feature guest speaker Harel Shaked, Technical Project Manager at Outbrain. He will review how Outbrain:
- Improved sales productivity “with the click of a button” to send and sign contracts and agreements
- Began closing deals within minutes from the time an order is sent
- Lowered contract processing time by several hours
Register now to learn how Outbrain utilized DocuSign to improve the efficiency and effectiveness of their sales operations.
This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the point-of-care testing industry. We will also be joined by Paul Pickering, president and CEO, Ubiquitome, and Herbert Torfs, VP Business Development and Strategy, GenePOC, who will discuss their experience with market trends, regulatory road blocks, and unaddressed needs in the US, Europe, and developing and underdeveloped nations.
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
Medical doctor Dheerandra Prasad talks about clinical prospects and his clinical experience of the Leksell Gamma Knife® Icon™ for precise, frameless and frame-based stereotactic radiosurgery of the brain.
Leksell Gamma Knife Icon combines the unprecedented accuracy of Gamma Knife with integrated immobilization, workflow and imaging technologies to provide even greater clinical flexibility for brain radiosurgery. This is due to a number of advancements, including on-board cone beam computer tomography, a thermoplastic mask system and an infrared-based high-definition motion-management system for patient tracking during treatment, which provide the opportunity to perform frameless and fractionated radiosurgery, as well as frame-based and single-session treatments, and to perform online adaptive planning.
Based on his experience as a radiation oncologist and a neurosurgeon, Dr Prasad discusses how these novel features of Gamma Knife Icon have opened up the possibility of extending Gamma Knife treatment to more patients and new indications. He will explain how the on-board CBCT imaging capabilities of Gamma Knife Icon have improved imaging workflows for both frame-based and frameless treatments at his clinic, and how the thermoplastic mask system has enabled him to treat targets outside the range of frame fixation. He also will describe how the ability to fractionate treatments has allowed him to expand his case mix, for example to patients with tumours that are situated close to critical structures, allowing such patients to benefit from the superior dosimetry of Gamma Knife.
Drawing from individual case studies and his personal experience, Dr Prasad will illustrate how Leksell Gamma Knife Icon is a valuable and flexible tool for brain radiosurgery and its role alongside linac-based stereotactic radiotherapy in today’s radiation oncology centres.
In the first in a series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Steven Meikle will examine the progression of medical physics over the last 60 years. He will discuss key developments in radiation therapy, cancer diagnosis and surgery, and describe some of the underlying technologies that enabled this medical physics revolution.
Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
– How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
– How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
– How real world video content can engage your key stakeholders and ensure customer insights drive action
Frost & Sullivan predicts the $100 genome will be achieved by 2024 should new technology launches continue at the current pace. This milestone will disrupt the services space both positively and negatively, as some customers will opt to bring sequencing in-house at that price point, while others that continue to outsource will greatly expand their large-scale sequencing projects. A new business model of answer-based sequencing services is likely to emerge in 10 years.
Demystify the process of writing and submitting your research with practical tips on selecting the right journal, handling feedback, bouncing back from rejection and streamlining the writing process.
Wiley Author Services presents Publishing Secrets for Early Career Researchers in Nursing. If you’re new to research or want to know more about the process, this webinar will give you practical guidance on:
•Selecting the RIGHT Journal
•Preparing your article – How to follow author guidelines
•Peer Review/Rejection – How to address reviewers comments
•Post publication and SEO – How to promote your work
With expert advice from top editors in the nursing research community you’ll discover all you need to help you successfully publish your next article.
Susan Gennaro, RN, PhD, FAAN
Dean and Professor, Boston College
Editor-in-Chief of Journal of Nursing Scholarship
Bernadette Mazurek Melnyk, PhD, RN, CPNP/PMHNP, FAANP, FNAP, FAAN
Dean, Associate Vice President for Health Promotion, Chief Wellness Officer, Ohio State University
Editor-in-Chief of Worldviews on Evidence-Based Nursing
Charon A. Pierson, PhD, GNP, FAANP, FAAN
Journal of the American Association of Nurse Practitioners
Professor Roger Watson,University of Hull
Faculty of Health and Social Care
BSc, PhD, RN, FRSB, FFNMRCSI, FRSA, FHEA, FEANS, FRCP Edin, FRCN, FAAN
Editor-in-Chief of Journal of Advanced Nursing
Dr. Mikael Roussel from the University Hospital of Rennes, France, will lead a discussion around the organization of the cell morphology and flow cytometry core laboratory. Hear his tips using Beckman Coulter's hematology solutions to improve management of patients with lymphocytosis. P.A.C.E. credit is available for your participation.*
The ImageStream is a multispectral imaging flow cytometer that generates high resolution images of cells at a rate of 1000’s of cells per second. This allows for the rapid acquisition of tens of thousands of images per sample. Using the IDEAS image analysis software, the system calculates features based not only on fluorescence intensity but the morphology of that fluorescence as well. With this novel approach the ImageStream is able to seamlessly combine the quantitative power of flow cytometry with the high content information associated with microscopy. The system can collect data on a wide range of applications including nuclear localization during a signal transduction cascade, measuring colocalization of two probes, or quantify features on the phagocytosed particles in macrophages.
During this webinar we will discuss the development of the Caltech High-Speed Multi-Color Camera (CHIMERA), using two Andor iXon Ultra 888 EMCCDs, for ground-based searches for occultations of sub-kilometre-sized KBOs, which it achieves through monitoring thousands of stars simultaneously.
CHIMERA has completed 20 nights of observing in 2015 and 2016, with an additional 50 nights observing to be completed by July 2018, yielding a final data set likely to have more than 100 occultation events.
For several years, professional astronomers have been looking to Andor as a source of extreme performance, exceptionally robust off-the-shelf detector solutions, utilized across many of the key observation sites worldwide. We will provide an overview of the key high-sensitivity, high-temporal-resolution detector technology types, used in diverse applications such as adaptive optics wavefront sensing, solar exploration, high-time-resolution astrophysics, transit exoplanet discovery, gravitational lensing and even customized guide cameras.
Are you new to publishing your research? Struggling to select a journal or understand Peer Review? In this webinar you’ll hear practical tips from top journal editors who’ll guide you through the publishing process and help you discover all you need to know to successfully publish your next article.
You’ll learn more about:
•Where to start if you’re thinking of publishing your research
•Selecting the right journal
•Writing and submitting your article
•Tools to help you through publication and beyond
Plus you’ll have the chance to ask the editors your questions and connect with fellow researchers attending from across the globe. Sign up today to reserve your place!
Childhood cancer and pediatric cancer are general terms used to describe a wide range of neoplasms found in children and teenagers. Occurring in approximately 1 in 300 people under the age of 20, compared to 1 in 6 adults, pediatric cancers are more rare than adult cancers. Because less is known about pediatric cancers, diagnosis can be quite challenging for pathologists.
This presentation covers the basic science, as well as facts and statistics about pediatric cancer. We will discuss how the utility of immunohistochemical testing along with the application of novel antibodies can contribute to accurate diagnosis and survival rates of pediatric cancer patients.
Sourcing for the manufacture and control of Antibody-Drug Conjugates (ADCs) used in clinical trials requires strategic planning, establishment of a specialized support network, and execution of several interdependent tasks. ADCs are complex molecules, a fusion of a biological, the monoclonal antibody (mAb), and of small molecules, the linker and the toxic payload. Facilities of acceptable standards for the handling of high potency materials need to be engaged, and there is a limited supply currently. This is further complicated by the fact that there is not one contract facility that has fully integrated services, a “one-stop shop” capable of mAb production, linker and/or payload synthesis, conjugation of mAb to linker-payload to make the Drug Substance, and finally, formulation of the ADC to make the Drug Product. Strategizing the best outsourcing practices for producing and testing ADCs, and establishing guiding principles for externalization to ensure the selection of the right CMOs for ADC outsourcing and technology transfer, will be further discussed.
Observable foreign and particulate matter has for a long time been recognized as a critical quality attribute for production of injectable protein formulations. Recently, a focus shift towards these particles and even smaller particles (particulate matter or subvisible particles) has been seen from the pharmaceutical industry, academia and the different regulatory bodies. Two of the central documents in this context are:
1. The FDA Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products1 and
Continuous bioprocessing offers potential to enhance productivity and product quality uniformity while simultaneously decreasing facility footprint and associated operational overhead. Advances in technology and increasing commercial pressures are leading to an increased interest in continuous processing across the biopharmaceutical sector. A number of companies are exploring and advancing continuous bioprocessing and this presents a range of opportunity and challenges, including the use of Process Analytical Technology (PAT) for process characterization, process control, and process robustness, in support of a Rapid Product Release (RPR) strategy.
Single-Use Process Analytical Technologies (PAT) tools have a great potential to not only increase process understanding at the seed stage but also simplify cell culture operations. By utilizing PAT, the risk from bioburden or contamination can be significantly reduced and the overall operating efficiency increased. In fact, PAT also provides a data-driven platform to integrate Process Development and Manufacturing Operations that can mitigate risks associated with technology/process transfer.